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Editorial
The miracle of brain neuropeptides: targeting
the brain oxytocin system is a true treatment
option in numerous psychiatric disorders
including schizophrenia
Dozens of neuropeptides of the brain act in con-
cert to regulate all aspects of behaviour and phys-
iological functions, including modulatory effects on
classical neurotransmitter systems. For example, neu-
ropeptides are involved in the fine-tuned regulation of
emotional and social behaviours, with some of them
exerting anxiolytic effects such as cholecystokinin-8
(CCK-8), prolactin, neuropeptide Y, the recently dis-
covered neuropeptide S, as well as oxytocin, and oth-
ers having opposite effects, thus increasing anxiety
levels such as corticotropin releasing factor (CRF)
or vasopressin. From an evolutionary point of view,
both a certain level of anxiety and fear responsive-
ness (to avoid danger), as well as a certain degree
of risk taking behaviour (to discover food resources
and mating partners), need to be in perfect balance
underlining the important regulatory capacity of these
neuropeptides. In addition to emotional behaviours,
various neuropeptides are key modulators of social
behaviours closely linked to emotionality and, there-
fore, summarised as socio-emotional behaviours.
In this context, there are lots of scientific and
clinical interests in the neuropeptide oxytocin,
which acts both as a blood neurohormone after
its secretion from the neurohypophysis, but also
as a brain neurotransmitter/neuromodulator when
released within distinct brain regions. This central
release can occur in several ways, for example, from
dendrites and perikarya within the hypothalamus, or
from axon terminals in limbic target regions. The
presence of oxytocin receptors in hypothalamic and
limbic regions, of which only one has been identified
to date, is the essential basis for its multiple socio-
emotional behaviours. In addition to its anxiolytic
actions, which have been shown in the amygdala and
the hypothalamic paraventricular nucleus in rodents
(1,2), oxytocin promotes prosocial behaviours –
many of them being in a reproductive context such as
maternal care and defence, mother-offspring bond-
ing, sexual behaviour or pair-bonding (for review
see 3–5). In addition, oxytocin plays a role in many
non-reproduction-related social behaviours such as
social recognition (6), social preference (7) and fear
extinction (8).
These findings together with the potential of
OXT to attenuate depression-related symptoms (9)
triggered a plethora of human studies with the aim to
pharmacologically target the brain oxytocin system
thus modulating emotional and physiological stress
coping, and social behaviours. Hereby, the method
of choice to increase oxytocinergic neurotransmis-
sion in the human brain is via intranasal application
under the assumption that oxytocin is taken up
into the brain compartment (10). Multiple effects
of intranasally applied oxytocin on (11) various
behavioural parameters and on neuronal activity
patterns as shown by functional magnet resonance
imaging (fMRI) studies confirm the high potential
of this psychopharmacotherapy also for clinical
use (for review see 12, 13). Just to provide a few
examples, intranasal oxytocin makes humans more
trusting (14), even under conditions of betrayal (15),
improves the learning performance especially when
reinforced by social cues, and increases emotional
empathy in men (to the level found in women which
was not affected by nasal oxytocin) (16). To further
underline the prosocial effects of oxytocin, it was
shown that oxytocin-treated subjects make more eye
movements towards the eye region when viewing
human faces (17), and show an improved ability
to read the mental state of others using social cues
from facial expressions (18). Further, after oxytocin
treatment anxiety levels in response to psychosocial
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stress (19), and neuronal responses to fearful faces
in the amygdala (20) were suppressed.
These studies mainly performed in healthy male
volunteers have been recently complemented by find-
ings of positive effects of oxytocin in patients with
autism spectrum disorder (21,22). In this context it
should be mentioned that a link between autism spec-
trum disorders and polymorphisms in the oxytocin
receptor gene and changes in oxytocin availability
have been described (for review see 12,13).
The review by MacDonald and Feifel in the
present issue of Archives of Neuropsychiatria
Scandinavia summarises existing evidence for the
potential of oxytocin as psychopharmacotherapy in
schizophrenia. Schizophrenia is characterised by
severe socio-emotional dysfunctions which, in most
cases, prevent the continuation of an independent
life. The currently available treatment options
include psychosocial intervention and antipsychotic
pharmacotherapies which mainly target the dopamine
(D2 receptor antagonism) and 5-HT (5-HT2A antag-
onism) systems. Therefore, it is exciting that two
independent double-blind, placebo-controlled US
studies could show promising first results with
intranasal oxytocin in schizophrenic patients (23,24).
In their review, MacDonald and Feifel provide a
comprehensive overview of the existing preclinical
and clinical findings on the potential use of oxytocin
as an antipsychotic drug. Thus, they outline the pre-
clinical experimental evidence for antipsychotic-like
effects of oxytocin, which should mainly involve
interactions with the dopaminergic (reward) system
of the nucleus accumbens and striatum, but also the
glutamatergic system. It is of note that in various
experimental settings oxytocin was able to restore
social deficits, e.g. after prenatal stress-induced
reduction of oxytocin expression (25), or after
social defeat-induced lack of social preference (7)
(for review see 5). Experimentally, the best model
of schizophrenia is the experimental induction of
deficits in prepuls inhibition (PPI), and in rats
oxytocin was able to restore PPI functions (26).
On the basis of these data, the brain oxytocin
system is likely to be altered in patients suffering
from schizophrenia, with altered plasma or cere-
brospinal fluid (CSF) oxytocin levels or morpho-
metric data indicating perturbations in the (central)
oxytocin system. However, as is the case also for
other psychopathologies, where brain oxytocin seems
to participate in its etiology such as depression (9) or
anxiety-related diseases including social phobia (13),
the difficulty exists to monitor the brain oxytocin sys-
tem of these patients, or at least to correlate plasma
parameters with the central neuropeptide system (27).
After the first clinical trials, which were per-
formed in the former Soviet Union in the 1960s
and 1970s with oxytocin applied intravenously or
intramuscularly (25 IU), there was a break of
30 years before clinical assessment of the effects of
oxytocin were restarted with a series of well-designed
clinical trials. In 2010, Feifel et al. (23) applied
oxytocin twice daily over 3 weeks to a cohort of
schizophrenic patients adjunctive to standard antipsy-
chotic therapy. In the third week of treatment a
significant, although, minor improvement of several
symptoms appeared, among them verbal memory. A
year later, Pedersen et al. (24) published a mod-
ified protocol, i.e. a shorter treatment duration (2
weeks). Again, oxytocin produced some therapeutic
effects and improved the Positive and Negative Syn-
drome Scale (PANSS score), which was mainly due
to a more pronounced improvement in various social
deficit symptoms such as restoration of the ability
of social judgement and cognition in oxytocin- ver-
sus placebo-treated patients. These promising studies
are supported by single-dose studies in schizophrenic
patients showing that oxytocin improved emotion
and social cognitive functions. In all these studies,
intranasal oxytocin seems well tolerated and safe.
All those fascinated by the multiple behavioural
functions of the oxytocin and vasopressin neuropep-
tide families and their underlying genetic and neu-
robiological mechanisms follow the development of
the human use of oxytocin with great interest, as
this system proved to be a true example for transla-
tional neuroscience. However, if we aim to develop
intranasal oxytocin treatment as an established thera-
peutic option (alone or possibly in combination with
other pharmacotherapies) for patients suffering from
schizophrenia, social phobia, depression or autism,
we need to invest substantial efforts into the neu-
robiology of nasally applied neuropeptides. In this
context, we need to reveal (a) routes and mechanisms
of uptake of oxytocin into the brain compartment,
(b) parenchymal diffusion or local accumulation,
(c) possible inhibitory or stimulatory interactions
with the endogenous oxytocin system including oxy-
tocin receptor up- or down-regulation, as well as (d)
gender-dependent and/or genetically determined vari-
ance in oxytocin responsiveness due to differences in
oxytocin receptor distribution and binding.
In conclusion, oxytocin receptor-mediated actions
are importantly involved in processing socio-
emotional stimuli with a certain level of activity of
the endogenous oxytocin system essential for pro-
tecting against emotional or social dysfunctions. The
review by MacDonald and Feifel further emphasises
that the brain oxytocin system seems to play an
antipsychotic role possibly by protecting against the
disruption of mesolimbic dopaminergic circuitries.
Thus, increasing the availability of bioactive (though
synthetic) oxytocin within the extracellular fluid of
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the brain by nasal application and, thus, increasing
the general activity of the brain oxytocin system
may compensate for possible dysfunctions in the
endogenous oxytocin system as suggested for
various psychopathologies such as social phobia,
depression, autism as well as schizophrenia.
Inga D. Neumann
Department of Behavioural and Molecular
Neurobiology, University of Regensburg,
Regensburg, Germany
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